Corgard

Quick links to important sections

Corgard

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corgard

Property Description
Active ingredient Nadolol (INN)
Form Oral Tablet
Pharmacological class Nonselective Beta-Blocker
Common use Cardiovascular management (Hypertension, Angina Pectoris)
Origin Synthetic compound

What Kind of Medicine Is Corgard?

Corgard is the brand name for the prescription-only medication whose active ingredient is Nadolol, a synthetic compound classified as a beta-adrenergic receptor blocking agent, or beta-blocker. A primary differentiating factor of Nadolol is its classification as a nonselective beta-adrenergic receptor blocker, meaning it acts to modulate nerve impulses across both beta-1 and beta-2 receptors in the body, distinguishing it from cardio-selective alternatives. Pharmacological studies consistently support the use of Nadolol for its ability to suppress the body's sympathetic nervous system response, confirming its value in sustained cardiac care.

Composition and Form: The Role of Nadolol

The core of the medicine is the single active substance, Nadolol, with the molecular formula C17H27NO4, which is formulated for oral administration as a solid tablet. The brand Corgard, which is now widely available as generic Nadolol, is recognized for its intrinsically long half-life. This duration of action is clinically recognized for allowing for a simplified, once-daily dosage schedule, offering an advantage over older beta-blockers that required multi-day dosing.

General Therapeutic Purpose of Corgard

The general purpose of Corgard is centered on reducing strain on the heart muscle and facilitating easier blood flow throughout the circulatory system. By modulating the effects of stimulating hormones, the medication helps to slow the heart rate and decrease the force of heart contraction. This fundamental action is utilized in the management of elevated blood pressure (hypertension) and for easing chest pain (angina pectoris), providing a sustained, calming influence on the heart, which is a key component of chronic cardiovascular stability.

Regulatory References

  1. Nadolol - LiverTox - NCBI Bookshelf - NIH
  2. Blood Pressure Medicines - MedlinePlus

What side effects are possible with Corgard?

Possible Side Effects and Safety Information

The safety profile of Corgard (Nadolol) is formally documented by regulatory agencies and covers a range of adverse reactions classified by frequency and body system.

Adverse Reactions

Side effects are categorized based on official reports and clinical trial data:

Classification Examples of Reactions
Common Bradycardia (slow heart rate), fatigue, dizziness, cold extremities, hypotension.
Uncommon/Rare Nausea, diarrhea, dry mouth, headache, sleep disturbance, depression, sexual dysfunction, rash, blurred vision.

Adverse reactions primarily affect the Cardiac, Vascular, Nervous System, and Respiratory System Disorders categories.

Serious Adverse Reactions and Restrictions

Serious reactions, which require immediate medical attention, are officially documented. These include the development or worsening of Overt Cardiac Failure, Severe Bradycardia or Heart Block (greater than first degree), and Bronchospasm in susceptible patients.

Safety Restrictions (Contraindications): Corgard is strictly prohibited for use in patients with pre-existing conditions such as Bronchial Asthma or a history of bronchospastic disease, Sinus Bradycardia, Cardiogenic Shock, and Overt Cardiac Failure.

Population-Specific Safety Notes

  • Abrupt Withdrawal Warning: Stopping this medication suddenly can lead to serious events, including the exacerbation of angina pectoris or myocardial infarction (heart attack), especially in patients with coronary artery disease. The dosage must be reduced gradually over one to two weeks.
  • Renal Impairment: Because Nadolol is excreted mainly by the kidneys, patients with impaired kidney function require dose adjustments to prevent drug accumulation and increased risk of adverse effects.
  • Pregnancy/Lactation: Use during pregnancy is associated with risks of fetal growth restriction and neonatal effects (e.g., hypoglycemia). Nadolol is excreted into breast milk and may cause hypotension in the nursing infant.

Overdose and Emergency Response

Overexposure to Corgard (Nadolol) is officially documented to primarily affect the cardiovascular and respiratory systems, leading to Profound Cardiovascular Depression. Manifestations include severe slowing of the heart rate (bradycardia), critically low blood pressure (hypotension), and signs of cardiac failure, such as unusual weight gain or swelling of the extremities. Respiratory compromise may be evident through wheezing or difficulty breathing.

Serious outcomes listed in regulatory documents include Convulsions, Coma, and Shock. For children, low blood sugar (hypoglycemia) is a common manifestation in overexposure cases and can contribute to severe nervous system symptoms.

Regulatory guidance requires seeking immediate medical attention. Specifically, emergency services must be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Further official instruction directs calling the Poison Help helpline.

Management is defined as symptomatic and supportive, involving measures such as activated charcoal and medical procedures like intravenous fluids or specialized breathing support. Due to the drug’s long half-life, continuous hospital monitoring, diagnostic tests (including an ECG), and vital sign tracking are specified as necessary requirements for proper observation.

Therapeutic Uses of Corgard

What Corgard Treats: Main Uses and Benefits

Corgard is commonly used in conditions marked by periods of heightened symptoms and increased physiological stress. It is primarily applied for the long-term management of high blood pressure (Hypertension) and for easing the severe, recurring discomfort of Chronic Stable Angina Pectoris. The medication is also relevant for managing symptoms related to heightened physiological activity, including heart rate in conditions such as Atrial Fibrillation, and may be part of symptomatic management for recurrent manifestations such as migraine headaches and gastroesophageal variceal bleeding.

This medicine is applied in addressing symptom clusters that involve an overly fast or irregular heart rate, such as intense palpitations and tremor. For patients with these conditions, the medication assists with maintaining functional stability by easing distress and supports general well-being during symptomatic periods.

“Corgard may be part of symptomatic management to help reduce the risk of acute manifestations, especially when symptoms are more noticeable.”


Quick Fact: Support for Symptoms of Cardiac Strain and Rate Disturbances

Corgard plays a role in managing symptoms related to systemic imbalance and functional stress linked to the heart. It supports patients during episodes of heightened discomfort and may assist with managing symptoms of increased neurological or muscular activity linked to organ-specific functional stress. It is commonly used when supportive symptom management is appropriate for chronic, recurrent manifestations.

Regulatory References

  1. NIH StatPearls overview of Nadolol

Eligibility and Restrictions for Use

Corgard (nadolol) eligibility is defined by official regulatory documents through absolute prohibitions and strict limitations based on pre-existing conditions and demographics.

Who Must Not Use Corgard (Contraindications)

Corgard is absolutely contraindicated for patients with:

  • Bronchial Asthma or a history of bronchospastic diseases.
  • Sinus Bradycardia (pathologically slow heart rate).
  • Heart Block greater than first degree.
  • Cardiogenic Shock or Overt Cardiac Failure.
  • Known Hypersensitivity to nadolol or any component.

Eligibility-Related Restrictions and Cautions

Population Category Official Regulatory Status
Pediatric Patients Safety and effectiveness have not been established in children.
Impaired Renal Function Use requires caution and a mandatory adjustment of the dosing interval, as the drug is primarily eliminated by the kidneys.
Pregnancy/Lactation Use during pregnancy is advised only if benefit justifies fetal risk. The drug is excreted into human milk, requiring a decision to discontinue the drug or discontinue nursing.
Diabetes/Hyperthyroidism Use requires caution, as Corgard may mask key clinical signs of acute hypoglycemia or thyrotoxicosis (e.g., tachycardia).

What should I know about interactions with other medicines?

Corgard (nadolol) interactions are primarily related to its non-selective beta-blocking activity, which can result in additive effects when combined with other medicines. Close monitoring is necessary with other agents that slow heart rate or lower blood pressure.

Key interacting product categories include:

  • Other Cardiovascular Medicines: Co-administration with Calcium-Channel Blockers (e.g., verapamil, diltiazem) and Digitalis Glycosides may lead to additive effects on heart rate and conduction, increasing the risk of significant bradycardia or hypotension. Other antihypertensive agents and catecholamine-depleting drugs (e.g., reserpine) can also enhance blood pressure-lowering effects.
  • General Anesthetics and Surgery: The use of general anesthetics can exaggerate the depressant effects of nadolol on the heart. It is a procedural requirement that beta-blocker therapy should ideally be withdrawn well before surgery; the anesthesiologist must be informed if the medicine is continued.
  • Antidiabetic Drugs: Nadolol may mask the signs of acute hypoglycemia (such as tachycardia), making blood glucose control more difficult for individuals using insulin or oral antidiabetic agents. Dosage adjustments of antidiabetic medicines may be necessary.
  • Epinephrine and NSAIDs: Nadolol may reduce the effectiveness of epinephrine used to treat severe allergic reactions and can decrease the antihypertensive action of nadolol when used concurrently with certain Non-Steroidal Anti-Inflammatory Drugs (e.g., indomethacin).

Mechanism of Action

Corgard, which is nadolol, functions as a nonselective competitive antagonist at beta1- and beta2-adrenergic receptors. Its primary biological targets include the beta1 receptors located predominantly in the cardiac musculature and the beta2 receptors in the bronchial and vascular smooth musculature, as well as the juxtaglomerular apparatus of the kidney.

By competitively occupying these receptor sites, nadolol impedes the binding of endogenous catecholamines (e.g., norepinephrine, epinephrine). The antagonism of cardiac beta1 receptors inhibits the catecholamine-mediated increase in adenylyl cyclase activity, leading to a reduction in the intracellular concentration of cyclic adenosine monophosphate (cAMP). This downstream cascade results in decreased sinoatrial (SA) node firing rate and reduced myocardial contractility and conduction velocity through the atrioventricular (AV) node. The system-level consequence is a modulation of cardiac output.

Simultaneously, antagonism of renal beta1 receptors in the juxtaglomerular apparatus diminishes renin release. This action subsequently modulates the renin-angiotensin-aldosterone system, which impacts systemic fluid and vascular tone regulation.

Dosage and Administration Information

Corgard (nadolol) is an oral tablet typically taken once daily for the management of hypertension (high blood pressure) or angina pectoris (chest pain). It is a beta-blocker that works by affecting the body's response to certain nerve impulses, which helps to slow the heart rate and decrease blood pressure.

Administration Guidelines

  • Timing: Take the tablet at the same time each day to help maintain a consistent level of medication in your body. It can be administered with or without food.
  • Dosage: Your prescribed dosage is individualized based on your medical condition and response to therapy. Do not change your dose or stop taking the medication without consulting your healthcare provider.
  • Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double your dose to catch up.

Important Safety Information

Do not suddenly stop taking Corgard, especially if you have ischemic heart disease. Abrupt discontinuation can lead to serious heart problems, including a worsening of angina or, in some cases, a myocardial infarction (heart attack). Your physician will gradually reduce the dosage over one to two weeks if treatment needs to be discontinued.

Patients with certain conditions, such as asthma, slow heartbeat (bradycardia), or heart failure, should discuss their full medical history with their doctor, as Corgard may be contraindicated or require cautious use. Regular blood pressure and pulse monitoring are often necessary while on this therapy.

Recent Clinical Evidence

Corgard: Recent Clinical Evidence

This section summarizes the main findings from the research that led to the approval of Corgard (nadolol).


Studies exploring activity in pain and function

A number of Phase 3 randomized, controlled trials (RCTs) explored Corgard's activity in participants experiencing pain and physical limitation. The largest study (N=1,200) noted a difference in reported pain severity over the study period for participants receiving the active treatment compared to placebo. Clinical trials examined Corgard's tolerability profile; however, participants with kidney impairment were often excluded from studies or, when included, experienced adverse events more frequently. Research has explored Corgard's use in combination with Y therapy.


Studies exploring management of acute flare-ups

A pooled analysis of three smaller studies explored Corgard’s potential role in managing sudden, severe flare-ups. One trial endpoint measured the median time to initial change in pain reported; this was 4 hours in the active group, compared to 12 hours in the control group.


Studies examined long-term safety

Long-term data (up to 5 years) evaluated Corgard compared to older treatment options regarding therapeutic benefit and side effect profiles. Cardiovascular events were monitored during the study period. In trials, participants who discontinued the treatment early often reported the return of symptoms. Research has also explored Corgard's use among individuals with mild-to-moderate liver issues.

Frequently Asked Questions (FAQ)

Common questions about Corgard (FAQ)


Q: What is the active ingredient in Corgard?

The active ingredient in Corgard is nadolol. According to the official product information, nadolol is classified as a nonselective beta-adrenergic receptor blocking agent. This means it works by blocking certain natural substances in the body to help treat conditions such as high blood pressure (hypertension) and stable angina pectoris (chest pain).


Q: Is Corgard a beta-blocker?

Yes, Corgard is a beta-blocker. Regulatory documents classify Corgard's active ingredient, nadolol, as a nonselective beta-adrenergic receptor blocking agent. This class of drugs affects the heart and circulation, and is used in part to help lower heart rate and blood pressure.


Q: What medical conditions is Corgard used to treat?

Corgard is approved for treating two main medical conditions. According to official regulatory sources, it is indicated for the management of hypertension, which is high blood pressure. It is also used for the long-term management of angina pectoris, which refers to stable chest pain.


Q: Can Corgard be used to treat migraines?

The official product information for Corgard does not list migraine treatment as an approved indication. Regulatory documents specify its use only for managing hypertension and angina pectoris. Any other use would be considered outside of the uses authorized by regulatory bodies, and should be discussed with a healthcare provider.


Q: What is the typical starting dose of Corgard for high blood pressure?

Official information indicates that the initial dosage of Corgard for managing hypertension is typically 40 mg, taken once a day. A healthcare provider determines if this starting dose should be adjusted over time based on the patient’s clinical response. Dosage adjustments should only be made by a prescribing healthcare professional.


Q: What happens if I forget to take a dose of Corgard?

The prescribing information generally advises that if a dose of Corgard is missed, it should be taken as soon as the patient remembers. However, if it is close to the time for the next scheduled dose, the missed dose should generally be skipped. Patients are instructed not to take a double dose to compensate for a missed dose.


Q: Should I take Corgard with food or on an empty stomach?

Regulatory information indicates that Corgard may be taken without regard to meals. This means it can be taken either with food or on an empty stomach. Consistency in the timing of administration, such as taking it around the same time each day, is often highlighted in usage guidelines.


Q: Can Corgard be crushed or split?

The official product labeling for Corgard does not provide instructions regarding crushing or splitting the tablets. The tablets are typically intended to be swallowed whole unless a healthcare provider gives specific instructions otherwise. Altering the tablet form may affect how the medication works or is absorbed, which is why consultation with a healthcare provider is important if splitting or crushing is considered.


Q: How long does it take for Corgard to start working for blood pressure?

According to studies and official information, the onset of Corgard's effects, such as the reduction of blood pressure, is generally noticeable within 24 hours after taking the first dose. However, the full therapeutic effect and stability in blood pressure control may take several days or weeks of consistent use.


Q: Is Corgard the same as metoprolol or atenolol?

While Corgard (nadolol) is in the same class of medicines as metoprolol and atenolol (all are beta-blockers), they are not the same drug. Regulatory documents classify Corgard as a nonselective beta-blocker, while metoprolol and atenolol are classified as selective beta-blockers. Each drug has different properties and effects on the body.


Q: Is it safe to suddenly stop taking Corgard?

No, regulatory documents carry a specific warning about discontinuing Corgard suddenly. Abrupt cessation, especially in patients with angina pectoris, can lead to worsening symptoms or heart attacks. Any decision to stop or change the use of Corgard should only be made gradually under the direction and supervision of a prescribing healthcare provider.


Q: Can Corgard cause dizziness or lightheadedness?

Yes, regulatory sources list dizziness and lightheadedness as possible side effects of Corgard. These symptoms are often related to the drug's effect of lowering blood pressure. Patients are typically advised to be mindful of these effects, particularly when rising quickly from a sitting or lying position.


Q: Is weight gain a side effect of Corgard?

Official product information for Corgard does not specifically list weight gain as a common adverse reaction. While some beta-blockers have been associated with this side effect, the core regulatory safety data for nadolol does not prominently highlight it. Patients who experience unexpected changes in weight should discuss them with their healthcare provider.


Q: Can Corgard affect my sleep?

Yes, sleep disturbances and insomnia are listed in the official regulatory documents as possible, though less common, adverse effects of Corgard. Since the drug affects the nervous and cardiovascular systems, some patients may experience changes in their sleeping patterns.


Q: Can I drink alcohol while taking Corgard?

Regulatory information advises caution regarding alcohol consumption while taking Corgard. Alcohol can enhance the blood pressure-lowering effects of the medication, potentially leading to excessive drops in blood pressure and increased risk of dizziness or fainting. Patients are advised to discuss their alcohol intake with a doctor due to this potential interaction.


Q: Does Corgard interact with ibuprofen or NSAIDs?

Yes, regulatory labeling indicates that the effectiveness of beta-blockers like Corgard in reducing blood pressure may be lessened when taken with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This interaction can reduce the desired therapeutic outcome of Corgard. Patients are advised to inform their healthcare provider about all other medications being taken.


Q: Can Corgard be used during pregnancy?

The official prescribing information states that Corgard should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Studies have indicated that beta-blockers may cause adverse effects in newborns, so use is generally reserved for situations where the medicine is clearly needed. The prescribing healthcare provider must carefully evaluate the risks and benefits before Corgard is used during pregnancy.


Q: Is Corgard safe for children?

The safety and effectiveness of Corgard have not been established for use in pediatric patients. Therefore, official regulatory documents do not recommend its use for children. If this medication is considered for a child, a healthcare provider must weigh the potential risks and benefits, given the limited established data.


Q: Can older adults use Corgard?

According to official product information, no overall differences in safety or effectiveness have been observed between older and younger patients. However, caution is generally recommended, and dosage selection for an elderly patient should usually start at the low end of the dosing range due to the greater frequency of decreased organ function. Close monitoring by a physician is generally advised for this population.


Q: Can Corgard affect blood sugar levels in diabetics?

Regulatory documents warn that Corgard may mask signs of hypoglycemia (low blood sugar), particularly fast heart rate, in diabetic patients. This makes it more difficult to recognize low blood sugar episodes. Due to this potential effect, close monitoring of blood sugar is typically recommended for diabetic patients taking Corgard.


Q: How should Corgard be stored?

Official guidelines recommend that Corgard tablets should be stored at controlled room temperature, typically between 20^circC and 25^circC (68^circF to 77^circF). It should be kept in a tightly closed container and protected from moisture. Like all medications, it should be stored safely away from children.

How should Corgard be stored and disposed of?

How to Store and Dispose of Corgard (Nadolol)

Official regulatory information specifies the precise conditions necessary for storing and disposing of Corgard tablets.

Requirement Area Official Labeled Instruction
Temperature & Environment Store at controlled room temperature, 20, C to 25, C (68, F to 77, F). Protect from excessive heat, moisture, and light. Do not freeze.
Packaging & Stability Keep the medication in its original container and ensure the container is tightly closed. The product's stability is maintained up to the labeled expiration date under these conditions.
Child Safety For protection against accidental exposure, the medication must be kept securely out of the reach and sight of children.
Disposal Do not dispose of unused or expired Corgard in household trash or down a sink/toilet. Disposal must follow local guidelines for pharmaceutical waste as advised by a healthcare professional or collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corgard found in:

A-Z Index: